The discovery and validation of new drug targets in cancer

Current Opinion in Biotechnology

Volumn 9, Issue 6, 1998, Pages 632-636

  Courtneidge, Sara A ^a   Plowman, Greg D ^a  

^a SUGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; NEW DRUG;

ANIMAL CELL; APOPTOSIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INVASION; CANCER THERAPY; CELL GROWTH; CELL SURVIVAL; DRUG DEVELOPMENT; DRUG TARGETING; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; VALIDATION PROCESS;

ANIMALIA;

EID: 0032402833     PISSN: 09581669     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0958-1669(98)80142-0     Document Type: Article

References (42)

1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other diseases. Nat Med. 1:1995;27-31.
2. Augustin HG. Antiogenic tumour therapy: will it work? Trends Pharmacol Sci. 19:1998;216-222.
3. Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res. 58:1998;1408-1416.
4. Pluda JM. Tumor-associated angiogenesis: mechanisms, clinical implications, and therapeutic strategies. Semin Oncol. 24:1997;203-218.
5. Kumagai A, Dunphy WG. Purification and molecular cloning of PIx1, a Cdc25-regulatory kinase from Xenopus egg extracts. Science. 273:1996;1377-1380.
6. Smith MR, Wilson ML, Hamanaka R, Chase D, Kung H, Longo DL, Ferris DK. Malignant transformation of mammalian cells initiated by constitutive expression of the polo-like kinase. Biochem Biophys Res Commun. 234:1997;397-405.
7. Lane HA, Nigg EA. Antibody microinjection reveals an essential role for human polo-like kinase 1 (PIk1) in the functional maturation of mitotic centrosomes. J Cell Biol. 135:1996;1701-1713.
8. Bischoff JR, Anderson L, Zhu Y, Mossie K, Ng L, Souza B, Schryver B, Flanagan P, Clairvoyant F, Ginther C, et al. A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. of outstanding interest EMBO J. 17:1998;3052-3065 This paper describes the cloning of two human serine/threonine kinase (aurora 1 and aurora 2) related to Drosophila and yeast centrosomal proteins that are required for chromosome segregation. The authors demonstrate that the aurora1 and aurora2 proteins are cell-cycle-regulated and their expression is restricted to mitotic structures. They further demonstrate that aurora2 encodes a transforming protein, and that it maps to an amplicon present in 52% of primary human colorectal cancers.
9. Roberts BT, Farr KA, Hoyt MA. The Saccharomyces cerevisiae checkpoint gene BUB1 encodes a novel protein kinase. Mol Cell Biol. 14:1994;8282-8291.
10. Taylor SS, McKeon F. Kinetochore localization of murine BuB1 is required for normal mitotic timing and checkpoint response to spindle damage. of outstanding interest Cell. 89:1997;727-735 See annotaton to [11].
11. Cahill DP, Lengauer C, Yu J, Riggins GJ, Wilson JK, Markowitz SD, Kinzler KW, Vogelstein B. Mutations of mitotic checkpoint genes in human cancers. of outstanding interest Nature. 392:1998;300-303 This paper and Taylor 1997 [10] describe the sequence and function of mouse and human Bub1 kinase. Yeast Bub1 is required for a delay in anaphase entry in response to spindle disruption. Similarly, the mammalian counterparts localize to the kinetochore during mitosis, and expression of dominant negative mutants result in failure of cell-cycle arrest following spindle damage. Cahill suggest that Bub1 is involved in a spindle assembly checkpoint, and that a defective Bub1 results in chromosomal instability, a common trait of colorectal tumor cell lines. This study also found 2 of 19 primary colorectal tumors to contain mutant Bub1 alleles, and suggests that the resultant aneuploidy may play a role in tumor progression.
12. Pennisi E. Cell division gatekeepers identified. of special interest Science. 279:1998;477-478 An excellent review of presentations at the 1997 American Society for Cell Biology meeting describing the molecular basis of how a cell senses the proper alignment of chromosomes prior to entering anaphase.
13. Burgering BM, Coffer PJ. Protein B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature. 376:1995;599-602.
14. 2. Binding of these lipids results in activation of the AKT kinase.
15. Stokoe D, Stephens LR, Copeland T, Gaffney PR, Reese CB, Painter GF, Holmes AB, McCormick F, Hawkins PT. Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B. of outstanding interest Science. 277:1997;567-570 See annotaton to [16].
16. Alessi DR, Deak M, Casamayor A, Caudwell FB, Morrice N, Norman DG, Gaffney P, Reese CB, McDougall CN, Harbison D, et al. 3-Phosphoinositide-dependent protein kinase-1 (PDK1): structural and functional homology with the Drosophila DSTPK61 kinase. of outstanding interest Curr Biol. 7:1997;776-789 This paper and Stokoe , 1997 [15] describe the identification and cloning of PDK1, a kinase upstream of AKT. stimulated by phosphoinositide binding to its pleckstrin homology (PH) domain, resulting in phosphorylation of Thr308 of AKT.
17. Khwaja A, Rodriguez-Viciana P, Wennstrom S, Warne PH, Downward J. Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway. of special interest EMBO J. 16:1997;2783-2793 This paper demonstrates AKT activation, and cell survival, on adhesion of cells to matrix. They also show transforming Ras promotes survival of detached cells through activation of AKT.
18. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 91:1997;231-241.
19. del Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nunez G. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science. 278:1997;687-689.
20. Scheid MP, Duronio V. Dissociation of cytokine-induced phosphorylation of bad and activation of PKB/akt: involvement of MEK upstream of bad phosphorylation. Proc Natl Acad Sci USA. 95:1998;7439-7444.
21. Bellacosa A, de Feo D, Godwin AK, Bell DW, Cheng JQ, Altomare DA, Wan M, Dubeau L, Scambia G, Masciullo V, et al. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer. 64:1995;280-285.
22. Cheng JQ, Ruggeri B, Klein WM, Sonoda G, Altomare DA, Watson DK, Testa JR. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc Natl Acad Sci USA. 93:1996;3636-3641.
23. Baserga R. Controlling IGF-receptor function: a possible strategy for tumor therapy. Trends Biotechnol. 14:1996;150-152.
24. Kulik G, Klippel A, Weber MJ. Antiapoptotic signaling by the insulin-like growth factor receptor, phosphatidylinositol 3-kinase, and Akt. Mol Cell Biol. 17:1997;1595-1606.
25. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. of special interest Science. 279:1998;563-566 This retrospective study identifies plasma IGF-1 levels as a predictor of prostate cancer risk.
26. Wu YC, Horvitz HR. C. elegans phagocytosis and cell-migration protein CED-5 is similar to human DOCK180. of outstanding interest Nature. 392:1998;501-504 This paper describes the cloning and characterization of C. elegans ced-5, a gene required for engulfment of cell corpses during programmed cell death in worms. The protein is similar to human DOCK180, which has been implicated in signaling of cell movement through tyrosine kinases. These findings provide important clues to understanding the molecular events of apoptosis.
27. Hasegawa H, Kiyokawa E, Tanaka S, Nagashima K, Gotoh N, Shibuya M, Kurata T, Matsuda M. DOCK180, a major CRK-binding protein, alters cell morphology upon translocation to the cell membrane. Mol Cell Biol. 16:1996;1770-1776.
28. Erickson MR, Galletta BJ, Abmayr SM. Drosophila myoblast city encodes a conserved protein that is essential for myoblast fusion, dorsal closure, and cytoskeletal organization. J Cell Biol. 138:1997;589-603.
29. Raymond E, Sun D, Chen SF, Windle B, von Hoff DD. Agents that target telomerase and telomeres. Curr Opin Biotechnol. 7:1996;583-591.
30. Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB, Harley CB, Shay JW, Lichtsteiner S, Wright WE. Extension of life-span by introduction of telomerase into normal human cells. of special interest Science. 279:1998;349-352 This paper is the first to demonstrate that telomerase activity can reverse cell senescence and extent lifespan of primary human cells.
31. Keely PJ, Westwick JK, Whitehead IP, Der CJ, Parise LV. Cdc42 and Rac1 induce integrin-mediated cell motility and invasiveness through PI(3)K. of special interest Nature. 390:1997;632-636 Expression of activating mutations in Cdc42 and Rac in T477 breast cancer cells induce migration on a collagen substrate and invasion through collagen gels, in a PI3-K dependent manner. These findings provide a possible mechanism for the metastatic progression of tumors.
32. Shaw LM, Rabinovitz I, Wang HH, Toker A, Mercurio AM. Activation of phosphoinositide 3-OH kinase by the α6β4 integrin promotes carcinoma invasion. Cell. 91:1997;949-960.
33. Schwartz MA. Integrins, oncogenes, and anchorage independence. J Cell Biol. 139:1997;575-578.
34. Schneller M, Vuori K, Ruoslahti E. αVβ3 integrin associates with activated insulin and PDGFbeta receptors and potentiates the biological activity of PDGF. EMBO J. 16:1997;5600-5607.
35. Alves F, Vogel W, Mossie K, Millauer B, Hofler H, Ullrich A. Distinct structural characteristics of discoidin I subfamily receptor tyrosine kinases and complementary expression in human cancer. Oncogene. 10:1995;609-618.
36. Barker KT, Martindale JE, Mitchell PJ, Kamalati T, Page MJ, Phippard DJ, Dale TC, Gusterson BA, Crompton MR. Expression patterns of the novel receptor-like tyrosine kinase, DDR, in human breast tumours. Oncogene. 10:1995;569-575.
37. Vogel W, Gish GD, Alves F, Pawson T. The discoidin domain receptor tyrosine kinases are activated by collagen. of outstanding interest Mol Cell. 1:1997;13-23 See annotation to [38].
38. Shrivastava A, Radziejewski C, Campbell E, Kovac L, McGlynn M, Ryan TE, Davis S, Goldfarb MP, Glass DJ, Lemke G, et al. An orphan receptor tyrosine kinase family whose members serve as non-integrin collagen receptors. of outstanding interest Mol Cell. 1:1997;25-34 This paper and Vogel 1997 [37], demonstrate the direct activation of the DDR1 and DDR2 tyrosine kinase receptors by collagen. Collagen binding results in a delayed autophosphorylation of DDR and subsequent association with SHC, yet no activation of MAP kinase. Vogel [37], also observe that collagen-induced activation of DDR2 results in upregulation of matrix metalloproteinase-1 (MMP1), and suggest this may be a mechanism to promote tumor escape and metastasis.
39. Schlessinger J. Direct binding and activation of receptor tyrosine kinases by collagen. Cell. 91:1997;869-872.
40. Hunter T. Oncoprotein networks. Cell. 88:1997;333-346.
41. Radeva G, Petrolcelli T, Behrend E, Leung-Hagesteijn C, Filmus J, Slingerland J, Dedhar S. Overexpression of the integrin-linked kinase promotes anchorage-independent cell cycle progression. J Biol Chem. 272:1997;13937-13944.
42. Wu C, Keightley SY, Leung-Hagesteijn C, Radeva G, Coppolino M, Goicoechea S, McDonald JA, Dedhar S. Integrin-linked protein kinase regulates fibronectin matrix assembly, E-cadherin expression, and tumorigenicity. J Biol Chem. 273:1998;528-536.